World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
105
Citations
60931
World Ranking
6661
National Ranking
3522

Overview

Robert Z. Orlowski is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a specialized focus on subfields including Hematology, Molecular Biology, Oncology, Genetics, and Immunology.

Their work addresses key topics such as Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Cancer Treatment and Pharmacology, Peptidase Inhibition and Analysis, Chronic Myeloid Leukemia Treatments, Chronic Lymphocytic Leukemia Research, and Amyloidosis: Diagnosis, Treatment, Outcomes.

Some of the recent papers Robert Z. Orlowski has contributed to include:

  • Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial, 2020, Blood
  • Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma, 2022, New England Journal of Medicine
  • Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial, 2021, The Lancet Oncology
  • Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT), 2020, Blood Cancer Journal
  • Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial, 2020, The Lancet Oncology

Frequent collaborators in their research include:

  • Hans C. Lee
  • Krina K. Patel
  • Sheeba K. Thomas
  • Muzaffar H. Qazilbash
  • Qaiser Bashir

The venues where Robert Z. Orlowski has often published studies are:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Transplantation and Cellular Therapy
  • Journal of Clinical Oncology
  • UNC Libraries

Best Publications

  • A phase 2 study of bortezomib in relapsed, refractory myeloma.

    Paul G. Richardson;Bart Barlogie;James Berenson;Seema Singhal

  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie

  • Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

    Antonio Palumbo;Hervé Avet-Loiseau;Stefania Oliva;Henk M. Lokhorst

  • Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

    Meletios A. Dimopoulos;Albert Oriol;Hareth Nahi;Jesus San-Miguel

  • Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

    Abstr Act;Sagar Lonial;Meletios Dimopoulos;Antonio Palumbo

  • Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

    S. Vincent Rajkumar;Jean Luc Harousseau;Brian Durie;Kenneth C. Anderson

  • Proteasome inhibitors in cancer therapy

    Elisabet E. Manasanch;Robert Z. Orlowski

  • Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

    A. Palumbo;S. V. Rajkumar;M. A. Dimopoulos;P. G. Richardson

  • Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

    Meletios Athanasios Dimopoulos;Philippe Moreau;Antonio Palumbo;Douglas Edgar Joshua

  • Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

    S. K. Kumar;J. H. Lee;J. J. Lahuerta;G. Morgan

  • Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

    Brian G.M. Durie;Antje Hoering;Muneer H. Abidi;S. Vincent Rajkumar

  • Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

    Sagar Lonial;Brendan M Weiss;Saad Z Usmani;Seema Singhal

  • Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies

    Robert Z. Orlowski;Thomas E. Stinchcombe;Beverly S. Mitchell;Thomas C. Shea

  • Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

    Pieter Sonneveld;Hervé Avet-Loiseau;Sagar Lonial;Saad Usmani

  • Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression

    Robert Z. Orlowski;Arnon Nagler;Pieter Sonneveld;Joan Bladé

  • Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

    Thierry Facon;Shaji Kumar;Torben Plesner;Robert Z Orlowski

  • Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

    Deborah J. Kuhn;Qing Chen;Peter M. Voorhees;John S. Strader

  • A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

    David S. Siegel;Thomas Martin;Michael Wang;Ravi Vij

  • Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib

    Paul G. Richardson;Hannah Briemberg;Sundar Jagannath;Patrick Y. Wen

  • NF-κB as a therapeutic target in cancer

    Robert Z Orlowski;Albert S Baldwin

Frequent Co-Authors

Richard E. Champlin
Richard E. Champlin The University of Texas MD Anderson Cancer Center
Sagar Lonial
Sagar Lonial Emory University
Paul G. Richardson
Paul G. Richardson Harvard University
Partow Kebriaei
Partow Kebriaei The University of Texas MD Anderson Cancer Center
Pieter Sonneveld
Pieter Sonneveld Erasmus University Rotterdam
David S. Siegel
David S. Siegel Hackensack University Medical Center
Saad Z. Usmani
Saad Z. Usmani Memorial Sloan Kettering Cancer Center
Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens
Elizabeth J. Shpall
Elizabeth J. Shpall The University of Texas MD Anderson Cancer Center
Ravi Vij
Ravi Vij Washington University in St. Louis

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring related online degrees opens diverse career pathways in the U.S. healthcare field. While traditional medical degrees remain highly competitive, remote learning programs in areas like nursing and healthcare administration are experiencing rapid growth.

For those seeking a quicker entry into healthcare, accredited lpn online programs prepare students for practical nursing roles with flexibility and speed. Registered nurses looking to specialize in mental health may consider enrolling in psych np programs, which train nurses for advanced practice in psychiatric and mental health care.

On the administrative side, earning a Master of Healthcare Administration (MHA) is more convenient than ever, thanks to the rise of fully remote options. To get started, explore some of the best online mha programs that combine academic excellence with online accessibility. Budget-conscious students can also find the cheapest mha online programs to further their leadership ambitions without excessive financial burden.

Whether your interest is in patient care or healthcare management, these online pathways provide accessible options to build a successful healthcare career in the USA.

Best Scientists Citing Robert Z. Orlowski

Trending Scientists